The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

about

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

Item

http://www.wikidata.org/entity/Q55432585

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@en

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@nl

type

Item

label

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@en

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@nl

prefLabel

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@en

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

@nl

P1476

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

@en

P2093

Amy Knehans

http://www.w3.org/2001/XMLSchema#string

Joshua P Kesterson

http://www.w3.org/2001/XMLSchema#string

Laura Parisi

http://www.w3.org/2001/XMLSchema#string

Linda Li

http://www.w3.org/2001/XMLSchema#string

Michael Roche

http://www.w3.org/2001/XMLSchema#string

Rebecca Phaeton

http://www.w3.org/2001/XMLSchema#string

P2860

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.

A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.

P304

346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/ONCOL.2018.346

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29983902

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

6007165

http://www.w3.org/2001/XMLSchema#string